urea has been researched along with ritonavir in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Bold, G; Capraro, HG; Goutte, G; Klimkait, T; Lazdins, JK; Mestan, J; Walker, MR | 1 |
Bacheler, LT; Cordova, B; De Lucca, GV; Erickson-Viitanen, S; Garber, S; Kim, UT; Klabe, RM; Ko, SS; Lam, GN; Liang, J; Logue, KA; Trainor, GL; Wright, MR | 1 |
Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K | 1 |
Kempf, DJ; Klein, LL; Lin, S; Marsh, KC; McDonald, EJ; Mo, H; Norbeck, DW; Park, C; Saldivar, A; Sham, HL; Stewart, KD; Stoll, VS; Sun, M; Vasavanonda, S; Zhao, C | 1 |
Gyémánt, N; Hilgeroth, A; Molnár, J; Richter, M | 1 |
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ | 1 |
Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
2 trial(s) available for urea and ritonavir
Article | Year |
---|---|
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Outpatients; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ritonavir; RNA, Viral; Sulfones; Urea; Young Adult | 2010 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
6 other study(ies) available for urea and ritonavir
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.
Topics: Anti-HIV Agents; Carbamates; Cell Line; Cells, Cultured; Ethylenes; Furans; HIV Protease Inhibitors; HIV Seronegativity; HIV-1; Humans; Indinavir; Kinetics; Lymphocytes; Orosomucoid; Ritonavir; Saquinavir; Sulfonamides; Urea; Virus Replication | 1997 |
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Azepines; Biological Availability; Cell Line; Chromatography, High Pressure Liquid; Dogs; Drug Design; Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Indazoles; Mutation; Ritonavir; RNA, Viral; Structure-Activity Relationship; Transcription, Genetic; Urea | 1998 |
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea | 2000 |
Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Topics: Aza Compounds; Drug Design; Drug Resistance, Multiple; HIV Protease Inhibitors; HIV-1; Ligands; Microbial Sensitivity Tests; Models, Molecular; Ritonavir; Structure-Activity Relationship; Urea | 2005 |
P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Azepines; Cell Line, Tumor; HIV Protease Inhibitors; Intestinal Absorption; Male; Mice; Permeability; Rats; Rats, Wistar; Ritonavir; Urea | 2006 |